Lebrikizumab gets European nod for treating moderate-to-severe atopic dermatitis.

The European Commission has approved lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who have failed topical therapies. Lebrikizumab selectively targets interleukin-13 and inhibits its signaling pathway. The approval was based on data from three pivotal phase 3 studies, which showed significant clinical efficacy of lebrikizumab compared to placebo. Lebrikizumab will first be available in Germany, with a rollout in other European countries expected through 2024. The drug remains under review in the United States. [Extracted from the article]